End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.18 USD | +6.91% | +2.20% | -4.35% |
Feb. 25 | Birzeit Pharmaceuticals Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 09 | What does the Gotham City report say about Grifols? | RE |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Palestine
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 84-03-31 |
Director of Finance/CFO | - | 84-11-14 | |
Chief Tech/Sci/R&D Officer | - | 97-01-31 | |
Chief Tech/Sci/R&D Officer | 71 | 77-04-02 | |
Chief Administrative Officer | 54 | 91-12-31 | |
Comptroller/Controller/Auditor | - | 98-09-08 | |
Human Resources Officer | - | 09-01-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-12-31 | |
Chief Administrative Officer | 54 | 91-12-31 | |
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 84-03-31 |
Director/Board Member | - | 84-04-29 | |
Director/Board Member | - | 90-07-29 | |
Director/Board Member | - | 92-05-27 | |
Director/Board Member | - | 11-04-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,764,898 | 28,654,287 ( 73.92 %) | 0 | 73.92 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-4.35% | 162M | |
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B | |
-2.27% | 4.81B |
- Stock Market
- Equities
- BPC Stock
- Company Birzeit Pharmaceuticals Company